• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center



Targeted Therapies for Glioma

The primary objective of the Dana-Farber/Harvard Cancer Center (DF/HCC) brain cancer SPORE is to improve the standard of care for gliomas through the use of targeted therapies. Towards this end, basic scientists from Harvard Medical School have joined with clinical/translational investigators from Brigham and Women's Hospital, Dana-Farber Cancer Institute, and Massachusetts General Hospital. This initiative is supported by central cores for Pathology, Biostatistics, and Administration, and includes career and developmental programs. The research program uses clinical materials and exploits a number of clinical trials to attack glioblastoma on four distinct fronts:


Project 1
Project 2
Project 3
Project 4


Core A - Pathology
Core B - Biostatistics
Core C - Administration

Principal Investigator:
Tracy Batchelor, MD (MGH)

Co-Principal Investigator:
Charles Stiles, PhD (DFCI)